Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208. doi:10.1016/S0140-6736(14)60493-1
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075–2085. doi:10.1016/S0140-6736(10)61424-9
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Kumar S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2017;52(1):34–40. doi:10.1038/bmt.2016.214
   PubMed Web of Science ®Google Scholar
• Ciftciler R, Goker H, Buyukasik Y, et al. Impact of pre-transplant and post-transplant remission status of patients on survival in newly diagnosed multiple myeloma. Indian J Hematol Blood Transfus. 2019;35(4):655–661. doi:10.1007/s12288-019-01108-7
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar SK, Dispenzieri A, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31(36):4529–4535. doi:10.1200/JCO.2013.49.0086
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Gertz MA, Dispenzieri A, et al. Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood. 2013;122(10):1746–1749. doi:10.1182/blood-2013-03-492678
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–147. doi:10.1056/NEJMoa2204925
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320. doi:10.1056/NEJMoa1611750
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749
   PubMed Web of Science ®Google Scholar
• Adams HC, 3rd, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95(3):279–289. doi:10.1002/cyto.a.23693
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848. doi:10.4049/jimmunol.1003032
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321. doi:10.1080/19420862.2015.1007813
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813. doi:10.4049/jimmunol.1501351
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474–3474. doi:10.1182/blood.V124.21.3474.3474
   Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38. doi:10.1016/S0140-6736(19)31240-1
   PubMed Web of Science ®Google Scholar
• Hulin C, Offner F, Moreau P, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021;106(8):2257–2260. doi:10.3324/haematol.2020.261842
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548–e548. doi:10.1016/S1470-2045(14)70442-5
   Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi:10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185(3):492–502. doi:10.1111/bjh.15806
   PubMed Web of Science ®Google Scholar
• Manjappa S, Fox R, Caimi PF, et al. Impact of daratumumab on stem cell collection, graft composition and engraftment. Blood. 2020;136(Supplement 1):35–37. doi:10.1182/blood-2020-142115
   Google Scholar
• Chhabra S, Callander NS, Costa LJ, et al. Stem cell collection with daratumumab (DARA)-based regimens in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts) in the Griffin and master studies. Blood. 2021;138(Supplement 1):2852–2852. doi:10.1182/blood-2021-149028
   Google Scholar
• Al Saleh AS, Sidiqi MH, Gertz MA, et al. Delayed neutrophil engraftment in patients receiving daratumumab as part of their first induction regimen for multiple myeloma. Am J Hematol. 2020;95(1):E8–E10. doi:10.1002/ajh.25654
   PubMed Web of Science ®Google Scholar
• Ma X, Wong SW, Zhou P, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018;7(1):27. doi:10.1186/s40164-018-0119-4
   PubMedGoogle Scholar
• Abhishek S, David M, Francis KB, et al. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody. Eur J Haematol. 2023 Aug;111(2):318-321.
   Google Scholar
• Frerichs KA, Bosman PWC, van Velzen JF, et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2020;105(6):e302–e306. doi:10.3324/haematol.2019.231860
   PubMed Web of Science ®Google Scholar
• Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009;9(1):201–209. doi:10.1111/j.1600-6143.2008.02461.x
   PubMed Web of Science ®Google Scholar
• Gomez AM, Willcox N, Vrolix K, et al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol. 2014;193(3):1055–1063. doi:10.4049/jimmunol.1301555
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474–1478. doi:10.1136/annrheumdis-2014-206016
   PubMed Web of Science ®Google Scholar
• Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107(9):3575–3583. doi:10.1182/blood-2005-05-2118
   PubMed Web of Science ®Google Scholar
• Giles AJ, Hutchinson MND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.
   PubMedGoogle Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197. doi:10.1016/S0140-6736(20)30734-0
   PubMed Web of Science ®Google Scholar
• Vitkon R, Netanely D, Levi S, et al. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. Ther Adv Hematol. 2021;12:20406207211035272. doi:10.1177/20406207211035272
   Web of Science ®Google Scholar
• Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079–2087. doi:10.3324/haematol.2018.194118
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096. doi:10.3324/haematol.2018.194282
   PubMed Web of Science ®Google Scholar